ID   3BHS2_HUMAN             Reviewed;         372 AA.
AC   P26439; A2RRA5; Q16010; Q53GD4; Q6AI10; Q6LDB9; Q99890; Q9UD08;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 182.
DE   RecName: Full=3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;
DE   AltName: Full=3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II;
DE            Short=3-beta-HSD II;
DE   AltName: Full=3-beta-HSD adrenal and gonadal type;
DE   Includes:
DE     RecName: Full=3-beta-hydroxy-Delta(5)-steroid dehydrogenase;
DE              EC=1.1.1.145;
DE     AltName: Full=3-beta-hydroxy-5-ene steroid dehydrogenase;
DE     AltName: Full=Progesterone reductase;
DE   Includes:
DE     RecName: Full=Steroid Delta-isomerase;
DE              EC=5.3.3.1;
DE     AltName: Full=Delta-5-3-ketosteroid isomerase;
GN   Name=HSD3B2; Synonyms=HSDB3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1741954; DOI=10.1089/dna.1991.10.701;
RA   Lachance Y., Luu-The V., Verreault H., Dumont M., Rheaume E.,
RA   Leblanc G., Labrie F.;
RT   "Structure of the human type II 3 beta-hydroxysteroid
RT   dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) gene: adrenal and
RT   gonadal specificity.";
RL   DNA Cell Biol. 10:701-711(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Adrenal gland;
RX   PubMed=1944309; DOI=10.1210/mend-5-8-1147;
RA   Rheaume E., Lachance Y., Zhao H.-F., Breton N., Dumont M.,
RA   de Launoit Y., Trudel C., Luu-The V., Simard J., Labrie F.;
RT   "Structure and expression of a new complementary DNA encoding the
RT   almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-
RT   isomerase in human adrenals and gonads.";
RL   Mol. Endocrinol. 5:1147-1157(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   GLN-94.
RC   TISSUE=Adrenal gland;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Small intestine;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 49-102.
RX   PubMed=7588414; DOI=10.3109/07435809509030466;
RA   Russell A.J., McCartin S., Corcao G., Burridge S.M., McBride M.W.,
RA   McNicol A.M., Hawes C.S., Mason J.I., Sutcliffe R.G.;
RT   "Variation in the expression of human 3 beta-hydroxysteroid
RT   dehydrogenase.";
RL   Endocr. Res. 21:485-494(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 167-205.
RX   PubMed=1363812; DOI=10.1038/ng0792-239;
RA   Rheaume E., Simard J., Morel Y., Mebarki F., Zachmann M., Forest M.G.,
RA   New M.I., Labrie F.;
RT   "Congenital adrenal hyperplasia due to point mutations in the type II
RT   3 beta-hydroxysteroid dehydrogenase gene.";
RL   Nat. Genet. 1:239-245(1992).
RN   [10]
RP   POSSIBLE INVOLVEMENT IN INSULIN-RESISTANT POLYCYSTIC OVARY SYNDROME.
RX   PubMed=14764797; DOI=10.1210/jc.2003-030934;
RA   Carbunaru G., Prasad P., Scoccia B., Shea P., Hopwood N., Ziai F.,
RA   Chang Y.T., Myers S.E., Mason J.I., Pang S.;
RT   "The hormonal phenotype of nonclassic 3 beta-hydroxysteroid
RT   dehydrogenase (HSD3B) deficiency in hyperandrogenic females is
RT   associated with insulin-resistant polycystic ovary syndrome and is not
RT   a variant of inherited HSD3B2 deficiency.";
RL   J. Clin. Endocrinol. Metab. 89:783-794(2004).
RN   [11]
RP   VARIANTS AH2 LYS-142; PRO-245 AND ASN-253.
RX   PubMed=8316254; DOI=10.1210/mend.7.5.8316254;
RA   Simard J., Rheaume E., Sanchez R., Laflamme N., de Launoit Y.,
RA   Luu-The V., van Seters A.P., Gordon R.D., Bettendorf M., Heinrich U.,
RA   Moshang T., New M.I., Labrie F.;
RT   "Molecular basis of congenital adrenal hyperplasia due to 3 beta-
RT   hydroxysteroid dehydrogenase deficiency.";
RL   Mol. Endocrinol. 7:716-728(1993).
RN   [12]
RP   VARIANTS AH2 TRP-108 AND LEU-186.
RX   PubMed=7833923; DOI=10.1093/hmg/3.9.1639;
RA   Sanchez R., Mebarki F., Rheaume E., Laflamme N., Forest M.G.,
RA   Bey-Omar F., David M., Morel Y., Labrie F., Simard J.;
RT   "Functional characterization of the novel L108W and P186L mutations
RT   detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a
RT   male pseudohermaphrodite with congenital adrenal hyperplasia.";
RL   Hum. Mol. Genet. 3:1639-1645(1994).
RN   [13]
RP   VARIANT AH2 ASP-254.
RX   PubMed=8126127; DOI=10.1210/jcem.78.3.8126127;
RA   Sanchez R., Rheaume E., Laflamme N., Rosenfield R.L., Labrie F.,
RA   Simard J.;
RT   "Detection and functional characterization of the novel missense
RT   mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta
RT   HSD) gene of a female patient with nonsalt-losing 3 beta HSD
RT   deficiency.";
RL   J. Clin. Endocrinol. Metab. 78:561-567(1994).
RN   [14]
RP   VARIANT AH2 ARG-129.
RX   PubMed=7962268; DOI=10.1210/jcem.79.4.7962268;
RA   Rheaume E., Sanchez R., Simard J., Chang Y.T., Wang J., Pang S.,
RA   Labrie F.;
RT   "Molecular basis of congenital adrenal hyperplasia in two siblings
RT   with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase
RT   deficiency.";
RL   J. Clin. Endocrinol. Metab. 79:1012-1018(1994).
RN   [15]
RP   VARIANT AH2 THR-82.
RX   PubMed=8185809; DOI=10.1677/jme.0.0120119;
RA   Mendonca B.B., Russell A.J., Vasconcelos-Leite M., Arnhold I.J.,
RA   Bloise W., Wajchenberg B.L., Nicolau W., Sutcliffe R.G., Wallace A.M.;
RT   "Mutation in 3 beta-hydroxysteroid dehydrogenase type II associated
RT   with pseudohermaphroditism in males and premature pubarche or cryptic
RT   expression in females.";
RL   J. Mol. Endocrinol. 12:119-122(1994).
RN   [16]
RP   VARIANT AH2 ARG-173.
RX   PubMed=8060486; DOI=10.1677/jme.0.0120225;
RA   Russell A.J., Wallace A.M., Forest M.G., Donaldson M.D., Edwards C.R.,
RA   Sutcliffe R.G.;
RT   "Mutation in the human gene for 3 beta-hydroxysteroid dehydrogenase
RT   type II leading to male pseudohermaphroditism without salt loss.";
RL   J. Mol. Endocrinol. 12:225-237(1994).
RN   [17]
RP   VARIANT AH2 ASP-15.
RX   PubMed=7893703; DOI=10.1021/bi00009a020;
RA   Rheaume E., Sanchez R., Mebarki F., Gagnon E., Carel J.-C.,
RA   Chaussain J.-L., Morel Y., Labrie F., Simard J.;
RT   "Identification and characterization of the G15D mutation found in a
RT   male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD)
RT   deficiency: alteration of the putative NAD-binding domain of type II 3
RT   beta-HSD.";
RL   Biochemistry 34:2893-2900(1995).
RN   [18]
RP   VARIANT AH2 PRO-205.
RX   PubMed=7633426; DOI=10.1093/hmg/4.4.745;
RA   Katsumata N., Tanae A., Yasunaga T., Horikawa R., Tanaka T., Hibi I.;
RT   "A novel missense mutation in the type II 3 beta-hydroxysteroid
RT   dehydrogenase gene in a family with classical salt-wasting congenital
RT   adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase
RT   deficiency.";
RL   Hum. Mol. Genet. 4:745-746(1995).
RN   [19]
RP   VARIANT AH2 ARG-259.
RX   PubMed=7633460; DOI=10.1093/hmg/4.5.969;
RA   Tajima T., Fujieda K., Nakae J., Shinohara N., Yoshimoto M., Baba T.,
RA   Kinoshita E., Igarashi Y., Oomura T.;
RT   "Molecular analysis of type II 3 beta-hydroxysteroid dehydrogenase
RT   gene in Japanese patients with classical 3 beta-hydroxysteroid
RT   dehydrogenase deficiency.";
RL   Hum. Mol. Genet. 4:969-971(1995).
RN   [20]
RP   VARIANT AH2 SER-100.
RX   PubMed=7608265; DOI=10.1210/jcem.80.7.7608265;
RA   Mebarki F., Sanchez R., Rheaume E., Laflamme N., Simard J.,
RA   Forest M.G., Bey-Omar F., David M., Labrie F., Morel Y.;
RT   "Nonsalt-losing male pseudohermaphroditism due to the novel homozygous
RT   N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase
RT   gene.";
RL   J. Clin. Endocrinol. Metab. 80:2127-2134(1995).
RN   [21]
RP   VARIANT AH2 SER-236.
RX   PubMed=9719627; DOI=10.1006/mgme.1998.2715;
RA   Nayak S., Lee P.A., Witchel S.F.;
RT   "Variants of the type II 3beta-hydroxysteroid dehydrogenase gene in
RT   children with premature pubic hair and hyperandrogenic adolescents.";
RL   Mol. Genet. Metab. 64:184-192(1998).
RN   [22]
RP   VARIANTS AH2 GLU-10; VAL-10; ASP-15; THR-82; SER-100; TRP-108;
RP   ARG-129; LYS-142; LEU-155; VAL-167; ARG-173; LEU-186; PRO-205;
RP   GLY-213; GLU-216; GLN-222; HIS-222; SER-236; PRO-245; ASN-253;
RP   ASP-254; ARG-259; MET-259 AND VAL-294.
RX   PubMed=10599696; DOI=10.1210/jcem.84.12.6288;
RA   Moisan A.M., Ricketts M.L., Tardy V., Desrochers M., Mebarki F.,
RA   Chaussain J.-L., Cabrol S., Raux-Demay M.C., Forest M.G.,
RA   Sippell W.G., Peter M., Morel Y., Simard J.;
RT   "New insight into the molecular basis of 3beta-hydroxysteroid
RT   dehydrogenase deficiency: identification of eight mutations in the
RT   HSD3B2 gene in eleven patients from seven new families and comparison
RT   of the functional properties of twenty-five mutant enzymes.";
RL   J. Clin. Endocrinol. Metab. 84:4410-4425(1999).
RN   [23]
RP   VARIANTS AH2 ARG-129; GLN-222 AND MET-259.
RX   PubMed=10651755; DOI=10.1046/j.1365-2265.2000.00873.x;
RA   Marui S., Castro M., Latronico A.C., Elias L.L., Arnhold I.J.,
RA   Moreira A.C., Mendonca B.B.;
RT   "Mutations in the type II 3beta-hydroxysteroid dehydrogenase (HSD3B2)
RT   gene can cause premature pubarche in girls.";
RL   Clin. Endocrinol. (Oxf.) 52:67-75(2000).
RN   [24]
RP   VARIANT AH2 GLU-10.
RX   PubMed=10843183; DOI=10.1210/jcem.85.5.6581;
RA   Alos N., Moisan A.M., Ward L., Desrochers M., Legault L., Leboeuf G.,
RA   van Vliet G., Simard J.;
RT   "A novel A10E homozygous mutation in the HSD3B2 gene causing severe
RT   salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX
RT   and 46,XY French-Canadians: evaluation of gonadal function after
RT   puberty.";
RL   J. Clin. Endocrinol. Metab. 85:1968-1974(2000).
RN   [25]
RP   VARIANTS AH2 LYS-142 AND THR-222.
RX   PubMed=12050213; DOI=10.1210/jcem.87.6.8559;
RA   Pang S., Wang W., Rich B., David R., Chang Y.T., Carbunaru G.,
RA   Myers S.E., Howie A.F., Smillie K.J., Mason J.I.;
RT   "A novel nonstop mutation in the stop codon and a novel missense
RT   mutation in the type II 3-beta-hydroxysteroid dehydrogenase (3-beta-
RT   HSD) gene causing, respectively, nonclassic and classic 3-beta-HSD
RT   deficiency congenital adrenal hyperplasia.";
RL   J. Clin. Endocrinol. Metab. 87:2556-2563(2002).
RN   [26]
RP   VARIANT AH2 LEU-341, AND CHARACTERIZATION OF VARIANT AH2 LEU-341.
RX   PubMed=18252794; DOI=10.1210/jc.2007-1874;
RA   Welzel M., Wustemann N., Simic-Schleicher G., Dorr H.G., Schulze E.,
RA   Shaikh G., Clayton P., Grotzinger J., Holterhus P.M., Riepe F.G.;
RT   "Carboxyl-terminal mutations in 3beta-hydroxysteroid dehydrogenase
RT   type II cause severe salt-wasting congenital adrenal hyperplasia.";
RL   J. Clin. Endocrinol. Metab. 93:1418-1425(2008).
RN   [27]
RP   VARIANT AH2 PRO-82.
RX   PubMed=22579964; DOI=10.1016/j.gene.2012.04.080;
RA   Rabbani B., Mahdieh N., Haghi Ashtiani M.T., Setoodeh A., Rabbani A.;
RT   "In silico structural, functional and pathogenicity evaluation of a
RT   novel mutation: an overview of HSD3B2 gene mutations.";
RL   Gene 503:215-221(2012).
CC   -!- FUNCTION: 3-beta-HSD is a bifunctional enzyme, that catalyzes the
CC       oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and
CC       the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic
CC       system plays a crucial role in the biosynthesis of all classes of
CC       hormonal steroids.
CC   -!- CATALYTIC ACTIVITY: A 3-beta-hydroxy-Delta(5)-steroid + NAD(+) = a
CC       3-oxo-Delta(5)-steroid + NADH.
CC   -!- CATALYTIC ACTIVITY: A 3-oxo-Delta(5)-steroid = a 3-oxo-Delta(4)-
CC       steroid.
CC   -!- PATHWAY: Lipid metabolism; steroid biosynthesis.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Single-pass
CC       membrane protein. Mitochondrion membrane; Single-pass membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P26439-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P26439-2; Sequence=VSP_037399, VSP_037400;
CC   -!- TISSUE SPECIFICITY: Expressed in adrenal gland, testis and ovary.
CC   -!- DISEASE: Adrenal hyperplasia 2 (AH2) [MIM:201810]: A form of
CC       congenital adrenal hyperplasia, a common recessive disease due to
CC       defective synthesis of cortisol. Congenital adrenal hyperplasia is
CC       characterized by androgen excess leading to ambiguous genitalia in
CC       affected females, rapid somatic growth during childhood in both
CC       sexes with premature closure of the epiphyses and short adult
CC       stature. Four clinical types: 'salt wasting' (SW, the most severe
CC       type), 'simple virilizing' (SV, less severely affected patients),
CC       with normal aldosterone biosynthesis, 'non-classic form' or late-
CC       onset (NC or LOAH) and 'cryptic' (asymptomatic). In AH2,
CC       virilization is much less marked or does not occur. AH2 is
CC       frequently lethal in early life. {ECO:0000269|PubMed:10599696,
CC       ECO:0000269|PubMed:10651755, ECO:0000269|PubMed:10843183,
CC       ECO:0000269|PubMed:12050213, ECO:0000269|PubMed:18252794,
CC       ECO:0000269|PubMed:22579964, ECO:0000269|PubMed:7608265,
CC       ECO:0000269|PubMed:7633426, ECO:0000269|PubMed:7633460,
CC       ECO:0000269|PubMed:7833923, ECO:0000269|PubMed:7893703,
CC       ECO:0000269|PubMed:7962268, ECO:0000269|PubMed:8060486,
CC       ECO:0000269|PubMed:8126127, ECO:0000269|PubMed:8185809,
CC       ECO:0000269|PubMed:8316254, ECO:0000269|PubMed:9719627}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=Mild HSD3B2 deficiency in hyperandrogenic females is
CC       associated with characteristic traits of polycystic ovary
CC       syndrome, such as insulin resistance and luteinizing hormone
CC       hypersecretion. {ECO:0000269|PubMed:14764797}.
CC   -!- SIMILARITY: Belongs to the 3-beta-HSD family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC60600.1; Type=Frameshift; Positions=186; Note=The frameshift is caused by a single nucleotide insertion which is found in AH2.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M77144; AAA36014.1; -; Genomic_DNA.
DR   EMBL; M67466; AAA36016.1; -; mRNA.
DR   EMBL; CR627415; CAH10504.1; -; mRNA.
DR   EMBL; AK222997; BAD96717.1; -; mRNA.
DR   EMBL; AL359553; CAC19799.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56700.1; -; Genomic_DNA.
DR   EMBL; BC038419; AAH38419.1; -; mRNA.
DR   EMBL; BC131488; AAI31489.1; -; mRNA.
DR   EMBL; S80140; AAD14329.1; -; Genomic_DNA.
DR   EMBL; S60309; AAC60599.1; -; Genomic_DNA.
DR   EMBL; S60310; AAC60600.1; ALT_FRAME; Genomic_DNA.
DR   CCDS; CCDS902.1; -. [P26439-1]
DR   PIR; A39488; DEHUH2.
DR   RefSeq; NP_000189.1; NM_000198.3. [P26439-1]
DR   RefSeq; NP_001159592.1; NM_001166120.1. [P26439-1]
DR   UniGene; Hs.654399; -.
DR   ProteinModelPortal; P26439; -.
DR   BioGrid; 109517; 20.
DR   STRING; 9606.ENSP00000358424; -.
DR   BindingDB; P26439; -.
DR   ChEMBL; CHEMBL3670; -.
DR   DrugBank; DB01285; Corticotropin.
DR   DrugBank; DB00603; Medroxyprogesterone acetate.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB01108; Trilostane.
DR   SwissLipids; SLP:000001296; -.
DR   iPTMnet; P26439; -.
DR   PhosphoSitePlus; P26439; -.
DR   BioMuta; HSD3B2; -.
DR   DMDM; 112770; -.
DR   PaxDb; P26439; -.
DR   PeptideAtlas; P26439; -.
DR   PRIDE; P26439; -.
DR   DNASU; 3284; -.
DR   Ensembl; ENST00000369416; ENSP00000358424; ENSG00000203859. [P26439-1]
DR   Ensembl; ENST00000543831; ENSP00000445122; ENSG00000203859. [P26439-1]
DR   GeneID; 3284; -.
DR   KEGG; hsa:3284; -.
DR   UCSC; uc001eht.4; human. [P26439-1]
DR   CTD; 3284; -.
DR   DisGeNET; 3284; -.
DR   GeneCards; HSD3B2; -.
DR   HGNC; HGNC:5218; HSD3B2.
DR   HPA; HPA043261; -.
DR   HPA; HPA043264; -.
DR   HPA; HPA044028; -.
DR   MalaCards; HSD3B2; -.
DR   MIM; 201810; phenotype.
DR   MIM; 613890; gene.
DR   neXtProt; NX_P26439; -.
DR   OpenTargets; ENSG00000203859; -.
DR   Orphanet; 90791; Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency.
DR   Orphanet; 3185; Polycystic ovary syndrome.
DR   PharmGKB; PA29487; -.
DR   eggNOG; KOG1430; Eukaryota.
DR   eggNOG; COG0451; LUCA.
DR   GeneTree; ENSGT00550000074557; -.
DR   HOVERGEN; HBG000014; -.
DR   KO; K00070; -.
DR   OMA; ACIQENV; -.
DR   OrthoDB; EOG091G09QZ; -.
DR   PhylomeDB; P26439; -.
DR   TreeFam; TF343138; -.
DR   BioCyc; MetaCyc:HS10943-MONOMER; -.
DR   BRENDA; 1.1.1.145; 2681.
DR   BRENDA; 5.3.3.1; 2681.
DR   Reactome; R-HSA-193048; Androgen biosynthesis.
DR   Reactome; R-HSA-193993; Mineralocorticoid biosynthesis.
DR   Reactome; R-HSA-194002; Glucocorticoid biosynthesis.
DR   UniPathway; UPA00062; -.
DR   GeneWiki; HSD3B2; -.
DR   GenomeRNAi; 3284; -.
DR   PRO; PR:P26439; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000203859; -.
DR   CleanEx; HS_HSD3B2; -.
DR   ExpressionAtlas; P26439; baseline and differential.
DR   Genevisible; P26439; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; NAS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; ISS:UniProtKB.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; ISS:UniProtKB.
DR   GO; GO:0031966; C:mitochondrial membrane; NAS:UniProtKB.
DR   GO; GO:0030868; C:smooth endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0003854; F:3-beta-hydroxy-delta5-steroid dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0004769; F:steroid delta-isomerase activity; IDA:UniProtKB.
DR   GO; GO:0006702; P:androgen biosynthetic process; TAS:Reactome.
DR   GO; GO:0006704; P:glucocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0006705; P:mineralocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0006694; P:steroid biosynthetic process; IDA:UniProtKB.
DR   InterPro; IPR002225; 3Beta_OHSteriod_DH/Estase.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   Pfam; PF01073; 3Beta_HSD; 1.
DR   SUPFAM; SSF51735; SSF51735; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome;
KW   Congenital adrenal hyperplasia; Disease mutation;
KW   Endoplasmic reticulum; Isomerase; Membrane; Mitochondrion;
KW   Multifunctional enzyme; NAD; Oxidoreductase; Polymorphism;
KW   Reference proteome; Steroidogenesis; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    372       3 beta-hydroxysteroid dehydrogenase/Delta
FT                                5-->4-isomerase type 2.
FT                                /FTId=PRO_0000087775.
FT   TRANSMEM    287    307       Helical. {ECO:0000255}.
FT   ACT_SITE    154    154       Proton acceptor. {ECO:0000250}.
FT   BINDING     158    158       NAD. {ECO:0000250}.
FT   VAR_SEQ     103    222       GTQLLLEACVQASVPVFIYTSSIEVAGPNSYKEIIQNGHEE
FT                                EPLENTWPTPYPYSKKLAEKAVLAANGWNLKNGDTLYTCAL
FT                                RPTYIYGEGGPFLSASINEALNNNGILSSVGKFSTVNP ->
FT                                ELQNKIKLTVLEGDILDEPFLKRACQDVSVVIHTACIIDVF
FT                                GVTHRQSIMNVNVKGRVAWGGDKARWGNEDQKEGQEGKRSL
FT                                SIEHLLCSGPSDFADHYQLGELKAAIFSFIDEKTRTEQ
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_037399.
FT   VAR_SEQ     223    372       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_037400.
FT   VARIANT      10     10       A -> E (in AH2; activity abolished;
FT                                dbSNP:rs28934880).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:10843183}.
FT                                /FTId=VAR_010517.
FT   VARIANT      10     10       A -> V (in AH2; nonsalt-wasting form).
FT                                {ECO:0000269|PubMed:10599696}.
FT                                /FTId=VAR_010518.
FT   VARIANT      15     15       G -> D (in AH2; activity abolished).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:7893703}.
FT                                /FTId=VAR_010519.
FT   VARIANT      74     74       D -> N (in dbSNP:rs4986954).
FT                                /FTId=VAR_048099.
FT   VARIANT      82     82       A -> P (in AH2).
FT                                {ECO:0000269|PubMed:22579964}.
FT                                /FTId=VAR_070028.
FT   VARIANT      82     82       A -> T (in AH2; dbSNP:rs757033996).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:8185809}.
FT                                /FTId=VAR_010520.
FT   VARIANT      94     94       E -> Q (in dbSNP:rs6211).
FT                                {ECO:0000269|PubMed:17974005}.
FT                                /FTId=VAR_014818.
FT   VARIANT     100    100       N -> S (in AH2; nonsalt-wasting form).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:7608265}.
FT                                /FTId=VAR_010521.
FT   VARIANT     108    108       L -> W (in AH2; activity abolished).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:7833923}.
FT                                /FTId=VAR_010522.
FT   VARIANT     129    129       G -> R (in AH2; nonsalt-wasting form;
FT                                dbSNP:rs587628683).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:10651755,
FT                                ECO:0000269|PubMed:7962268}.
FT                                /FTId=VAR_010523.
FT   VARIANT     142    142       E -> K (in AH2; activity abolished;
FT                                dbSNP:rs80358219).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:12050213,
FT                                ECO:0000269|PubMed:8316254}.
FT                                /FTId=VAR_000006.
FT   VARIANT     155    155       P -> L (in AH2; nonsalt-wasting form;
FT                                dbSNP:rs779418168).
FT                                {ECO:0000269|PubMed:10599696}.
FT                                /FTId=VAR_010524.
FT   VARIANT     167    167       A -> V (in AH2; late onset; almost normal
FT                                activity; dbSNP:rs35486059).
FT                                {ECO:0000269|PubMed:10599696}.
FT                                /FTId=VAR_010525.
FT   VARIANT     173    173       L -> R (in AH2; nonsalt-wasting form;
FT                                dbSNP:rs762479018).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:8060486}.
FT                                /FTId=VAR_010526.
FT   VARIANT     186    186       P -> L (in AH2; activity abolished).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:7833923}.
FT                                /FTId=VAR_010527.
FT   VARIANT     205    205       L -> P (in AH2).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:7633426}.
FT                                /FTId=VAR_000007.
FT   VARIANT     213    213       S -> G (in AH2; late onset; partial loss
FT                                of activity; dbSNP:rs759422374).
FT                                {ECO:0000269|PubMed:10599696}.
FT                                /FTId=VAR_010528.
FT   VARIANT     216    216       K -> E (in AH2; late onset; partial loss
FT                                of activity).
FT                                {ECO:0000269|PubMed:10599696}.
FT                                /FTId=VAR_010529.
FT   VARIANT     222    222       P -> H (in AH2; nonsalt-wasting form;
FT                                activity abolished).
FT                                {ECO:0000269|PubMed:10599696}.
FT                                /FTId=VAR_010530.
FT   VARIANT     222    222       P -> Q (in AH2; activity abolished;
FT                                dbSNP:rs765547422).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:10651755}.
FT                                /FTId=VAR_010531.
FT   VARIANT     222    222       P -> T (in AH2; dbSNP:rs80358220).
FT                                {ECO:0000269|PubMed:12050213}.
FT                                /FTId=VAR_015411.
FT   VARIANT     231    238       Missing (in AH2; activity abolished).
FT                                /FTId=VAR_010532.
FT   VARIANT     236    236       L -> S (in AH2; mild; 100% of activity;
FT                                dbSNP:rs35887327).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:9719627}.
FT                                /FTId=VAR_010533.
FT   VARIANT     245    245       A -> P (in AH2; loss of 88% of activity).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:8316254}.
FT                                /FTId=VAR_000008.
FT   VARIANT     253    253       Y -> N (in AH2; activity abolished).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:8316254}.
FT                                /FTId=VAR_000009.
FT   VARIANT     254    254       Y -> D (in AH2; activity abolished).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:8126127}.
FT                                /FTId=VAR_000010.
FT   VARIANT     259    259       T -> M (in AH2; activity abolished;
FT                                dbSNP:rs80358221).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:10651755}.
FT                                /FTId=VAR_010534.
FT   VARIANT     259    259       T -> R (in AH2; activity abolished).
FT                                {ECO:0000269|PubMed:10599696,
FT                                ECO:0000269|PubMed:7633460}.
FT                                /FTId=VAR_000011.
FT   VARIANT     294    294       G -> V (in AH2; nonsalt-wasting form;
FT                                activity abolished).
FT                                {ECO:0000269|PubMed:10599696}.
FT                                /FTId=VAR_010535.
FT   VARIANT     341    341       P -> L (in AH2; strongly reduced
FT                                activity; dbSNP:rs121964897).
FT                                {ECO:0000269|PubMed:18252794}.
FT                                /FTId=VAR_065665.
FT   CONFLICT     52     53       RT -> KI (in Ref. 8; AAD14329).
FT                                {ECO:0000305}.
FT   CONFLICT     92     94       HRE -> RRQ (in Ref. 8; AAD14329).
FT                                {ECO:0000305}.
FT   CONFLICT    232    232       H -> L (in Ref. 4; BAD96717).
FT                                {ECO:0000305}.
SQ   SEQUENCE   372 AA;  42052 MW;  8E0D933488988451 CRC64;
     MGWSCLVTGA GGLLGQRIVR LLVEEKELKE IRALDKAFRP ELREEFSKLQ NRTKLTVLEG
     DILDEPFLKR ACQDVSVVIH TACIIDVFGV THRESIMNVN VKGTQLLLEA CVQASVPVFI
     YTSSIEVAGP NSYKEIIQNG HEEEPLENTW PTPYPYSKKL AEKAVLAANG WNLKNGDTLY
     TCALRPTYIY GEGGPFLSAS INEALNNNGI LSSVGKFSTV NPVYVGNVAW AHILALRALR
     DPKKAPSVRG QFYYISDDTP HQSYDNLNYI LSKEFGLRLD SRWSLPLTLM YWIGFLLEVV
     SFLLSPIYSY QPPFNRHTVT LSNSVFTFSY KKAQRDLAYK PLYSWEEAKQ KTVEWVGSLV
     DRHKETLKSK TQ
//
